186RNL not checked
Cerenome · Rhenium-186 Nanoliposome
FollowEvery change as it happens, and a Monday email
Trials
4 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well…”In the company’s words, NCT01906385 on ClinicalTrials.gov
- Tested for
- Glioma (2 trials), Leptomeningeal Metastasis, Ependymoma, High Grade Gliomas
- Main trialPhase 1/2
- “This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.”In the company’s words, NCT01906385 on ClinicalTrials.gov
- Other names
- Retreatment Rhenium Liposome · Rhenium-186 Nanoliposome · Rhenium Liposome Treatment
Other drugs for Glioma
- 5-Aminolevulinic Acid Hydrochloride PowderLee's Pharmaceutical Limited · Phase 3
- DordaviproneJazz Pharmaceuticals · Phase 3
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
Coming up4
- Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Jul 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 1 Mar 2028Phase 1 trial completes · ClinicalTrials.gov
- Mar 2028Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT01906385
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Apr 2027 | Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | |
| Phase 1/2Recruiting | 31 Jul 2027 | Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases | |
| Phase 1Recruiting | 1 Mar 2028 | Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | |
| Phase 1Recruiting | Mar 2028 | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma | |
| Phase 1Completed | 19 Oct 2026 | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026